EP0386109A1 - Knochenbildungssbeschleunigung durch gm-csf - Google Patents

Knochenbildungssbeschleunigung durch gm-csf

Info

Publication number
EP0386109A1
EP0386109A1 EP88910226A EP88910226A EP0386109A1 EP 0386109 A1 EP0386109 A1 EP 0386109A1 EP 88910226 A EP88910226 A EP 88910226A EP 88910226 A EP88910226 A EP 88910226A EP 0386109 A1 EP0386109 A1 EP 0386109A1
Authority
EP
European Patent Office
Prior art keywords
bone
csf
treatment
stimulators
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP88910226A
Other languages
English (en)
French (fr)
Inventor
Hugh E. Black
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP0386109A1 publication Critical patent/EP0386109A1/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP88910226A 1987-11-12 1988-11-10 Knochenbildungssbeschleunigung durch gm-csf Pending EP0386109A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11961187A 1987-11-12 1987-11-12
US119611 1987-11-12

Publications (1)

Publication Number Publication Date
EP0386109A1 true EP0386109A1 (de) 1990-09-12

Family

ID=22385326

Family Applications (2)

Application Number Title Priority Date Filing Date
EP88910226A Pending EP0386109A1 (de) 1987-11-12 1988-11-10 Knochenbildungssbeschleunigung durch gm-csf
EP88310594A Withdrawn EP0318184A1 (de) 1987-11-12 1988-11-10 Knochenbildungbeschleunigung durch GM-CSF

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP88310594A Withdrawn EP0318184A1 (de) 1987-11-12 1988-11-10 Knochenbildungbeschleunigung durch GM-CSF

Country Status (6)

Country Link
EP (2) EP0386109A1 (de)
JP (1) JPH0649655B2 (de)
AU (1) AU638204B2 (de)
DK (1) DK116390A (de)
IL (1) IL88344A (de)
WO (1) WO1989004173A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89737T1 (de) * 1989-01-30 1993-06-15 Schering Corp Behandlung von leukozytstoerungen mit gm-csf.
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5206023A (en) * 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH0517367A (ja) * 1991-07-08 1993-01-26 Green Cross Corp:The 骨粗鬆症治療剤
US5270300A (en) * 1991-09-06 1993-12-14 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone
DE69233329T2 (de) * 1991-12-18 2004-08-05 Icu Medical, Inc., Irvine Verfahren zum Flüssigkeitstransfer
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP0891779A1 (de) * 1997-06-19 1999-01-20 Roche Diagnostics GmbH Pharmazeutische Kombinationspräparate enthaltend Parathyroidhormon und Calcium- und/oder Phosphatverbindungen
JP4709440B2 (ja) * 2001-08-20 2011-06-22 高山産業株式会社 通気路形成用のスペーサーおよびそのスペーサーを用いた壁体の通気路形成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR893138A (fr) * 1940-04-05 1944-05-31 Procédé de préparation d'un produit destiné à guérir les fractures des os
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
AU626530B2 (en) * 1987-07-17 1992-08-06 Schering Biotech Corporation Human granulocyte-macrophage colony stimulating factor and muteins thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8904173A1 *

Also Published As

Publication number Publication date
DK116390D0 (da) 1990-05-10
WO1989004173A1 (en) 1989-05-18
AU638204B2 (en) 1993-06-24
IL88344A0 (en) 1989-06-30
DK116390A (da) 1990-05-10
EP0318184A1 (de) 1989-05-31
IL88344A (en) 1994-06-24
AU2710388A (en) 1989-06-01
JPH02502642A (ja) 1990-08-23
JPH0649655B2 (ja) 1994-06-29

Similar Documents

Publication Publication Date Title
Nakamura et al. Recombinant human basic fibroblast growth factor accelerates fracture healing by enhancing callus remodeling in experimental dog tibial fracture
US7638486B2 (en) Method for promoting hard tissue formation
Foster et al. Advances in defining regulators of cementum development and periodontal regeneration
AU599031B2 (en) Regulation of degradation processes in bone
Wang et al. Thrombin peptide (TP508) promotes fracture repair by up‐regulating inflammatory mediators, early growth factors, and increasing angiogenesis
Guizzardi et al. Polydeoxyribonucleotide (PDRN) promotes human osteoblast proliferation: a new proposal for bone tissue repair
JPH09510209A (ja) 骨の成長を刺激するための繊維芽細胞成長因子の用途
EP0386109A1 (de) Knochenbildungssbeschleunigung durch gm-csf
Yamashita et al. Effects of Intermittent Administration of Parathyroid Hormone and Parathyroid Hormone Related Protein on Fracture Healing: A Narrative Review of Animal and Human Studies
Lucas et al. Stimulation of systemic bone formation induced by experimental blood loss.
EP1313440B1 (de) Dentalzubereitungen enthaltend peptide, die das knochenwachstum fördern
Bail et al. Recombinant species-specific growth hormone increases hard callus formation in distraction osteogenesis
Yao et al. CCL2 is a critical mechano-responsive mediator in crosstalk between osteoblasts and bone mesenchymal stromal cells
Schneider et al. The anabolic effects of vitamin D-binding protein-macrophage activating factor (DBP-MAF) and a novel small peptide on bone
Feng et al. Small blood stem cells for enhancing early osseointegration formation on dental implants: a human phase I safety study
WO2015057836A2 (en) Bone anabolic parathyroid hormone and parathyroid hormone related-protein analogs
CN111632147A (zh) 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用
Gandhi et al. Platelet releasate enhances healing in patients with a non-union
Laurina et al. Growth factors/cytokines/defensins and apoptosis in periodontal pathologies
Yuli et al. Effect of Aloe vera gel on the expression of FGF-2, TGF-β, and Smad3 in the root surface of rat teeth after Traumatic avulsion
Drakopoulos et al. Off-label use of teriparatide in spine
Chunxiao et al. Pharmacological effects of a recombinant hPTH (1− 34) derived peptide on ovariectomized rats
Morshed et al. Fracture healing
JPH07504160A (ja) 骨の再生
US20160220639A1 (en) Methods and compositions for treating bone diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19900515

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88310594.2/0318184 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 24.04.91.